GlassScriptPhysician profile
Paige H Warner
NPI 1831243815
$6,579.60
in general payments reported to CMS, 2019-2025
33 companies · $821 in 2025
The $821 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,108 · 2022: $3,212 · 2023: $861 · 2024: $577 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,884.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $757.54 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $402.53 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Polynovo North America LLC | $371.35 | 2025 | Novosorb Btm |
| Amgen INC. | $326.10 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $311.46 | 2021-2025 | Freestyle Libre 3 |
| Leica Microsystems INC. | $190.00 | 2023 | |
| Lilly USA, LLC | $181.70 | 2021-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $159.54 | 2021-2024 | Verquvo, Steglujan, Segluromet |
| Astellas Pharma US INC | $152.61 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.64 | 2021-2023 | Synjardy, Jardiance |
| Novo Nordisk INC | $106.95 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $100.24 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $61.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.67 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $52.32 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $44.93 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $43.38 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $30.22 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.23 | 2024-2025 | Xifaxan |
| Endo Pharmaceuticals INC. | $25.87 | 2021 | |
| Insulet Corporation | $24.79 | 2024 | Omnipod |
| Exact Sciences Corporation | $20.22 | 2025 | The Cologuard Plus Collection Kit |
| Ars Pharmaceuticals Operations, INC. | $19.79 | 2025 | Neffy |
| Eisai INC. | $14.37 | 2021 | |
| Sanofi Pasteur INC. | $14.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.63 | 2025 | Voquezna |
| Bausch Health US, LLC | $13.50 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.11 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.90 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.88 | 2021 | |
| Medtronic, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.